BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it withdrew the Registration Statement on Form S-1 it filed with the U.S.
December 6, 2022|
TransCode Therapeutics: Invitation to The ThinkEquity Conference Boston, Massachusetts--(Newsfile Corp. - October 19, 2022) -  TransCode Therapeutics  (NASDAQ: RNAZ), the RNA Oncology company committed to more effectively treating cancer using RNA therapeutics, will be participating in The
October 19, 2022|
Displaying 1 - 10 of 26